Longitudinal evaluation of serum pancreatic enzymes and ultrasonographic findings in diabetic cats without clinically relevant pancreatitis at diagnosis by Zini, Eric et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Longitudinal evaluation of serum pancreatic enzymes and ultrasonographic
findings in diabetic cats without clinically relevant pancreatitis at diagnosis
Zini, E; Hafner, M; Kook, P; Lutz, T A; Ohlerth, S; Reusch, C E
Abstract: BACKGROUND Cats with diabetes mellitus can have subclinical pancreatitis but prospective
studies to confirm this are lacking. Metabolic control of diabetic cats with pancreatitis is difficult.
HYPOTHESIS Subclinical pancreatitis occurs in diabetic cats at the time diabetes is diagnosed or might
develop during the follow-up period, hampering diabetic remission. ANIMALS Thirty cats with newly
diagnosed diabetes without clinical signs of pancreatitis on admission. METHODS Prospective study. On
admission and 2 and 6 months later, serum Spec fPL and DGGR-lipase were measured and the pancreas
underwent ultrasonographic examination. Pancreatitis was suspected if serum markers were increased or
￿2 ultrasonographic abnormalities were detected. Cats were treated with insulin glargine and diabetic
remission was defined as euglycemia ￿4 weeks after discontinuation of insulin. Nonparametric statistical
tests were used for analysis. RESULTS Subclinical pancreatitis at the time of diagnosis was suspected in
33, 50, and 31% of cats based on Spec fPL, DGGR-lipase and ultrasonography, respectively; and in 60%
when diagnostic criteria were combined. During the follow-up period, suspected pancreatitis developed in
additional 17-30% cats. Only 1 cat had transient clinical signs compatible with pancreatitis. Seventeen of
the 30 cats (57%) achieved remission. Frequency of abnormal Spec fPL and DGGR-lipase and abnormal
ultrasonographic findings did not differ in cats achieving remission and those who did not. Cats achieving
remission had significantly lower Spec fPL at 2 months (P < .001). CONCLUSIONS AND CLINICAL
IMPORTANCE Based on laboratory and ultrasonographic measurements, many cats with diabetes might
have pancreatitis, although without clinical signs. Cats with high Spec fPL might have a reduced chance
of diabetic remission; however, this topic needs further studies in large cohorts of diabetic cats.
DOI: 10.1111/jvim.12565
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-110225
Published Version
 
 
Originally published at:
Zini, E; Hafner, M; Kook, P; Lutz, T A; Ohlerth, S; Reusch, C E (2015). Longitudinal evaluation of serum
pancreatic enzymes and ultrasonographic findings in diabetic cats without clinically relevant pancreatitis
at diagnosis. Journal of Veterinary Internal Medicine, 29(2):589-596. DOI: 10.1111/jvim.12565
Longitudinal Evaluation of Serum Pancreatic Enzymes and
Ultrasonographic Findings in Diabetic Cats Without Clinically
Relevant Pancreatitis at Diagnosis
E. Zini, M. Hafner, P. Kook, T.A. Lutz, S. Ohlerth, and C.E. Reusch
Background: Cats with diabetes mellitus can have subclinical pancreatitis but prospective studies to conﬁrm this are lack-
ing. Metabolic control of diabetic cats with pancreatitis is diﬃcult.
Hypothesis: Subclinical pancreatitis occurs in diabetic cats at the time diabetes is diagnosed or might develop during the
follow-up period, hampering diabetic remission.
Animals: Thirty cats with newly diagnosed diabetes without clinical signs of pancreatitis on admission.
Methods: Prospective study. On admission and 2 and 6 months later, serum Spec fPL and DGGR-lipase were measured
and the pancreas underwent ultrasonographic examination. Pancreatitis was suspected if serum markers were increased or ≥2
ultrasonographic abnormalities were detected. Cats were treated with insulin glargine and diabetic remission was deﬁned as
euglycemia ≥4 weeks after discontinuation of insulin. Nonparametric statistical tests were used for analysis.
Results: Subclinical pancreatitis at the time of diagnosis was suspected in 33, 50, and 31% of cats based on Spec fPL,
DGGR-lipase and ultrasonography, respectively; and in 60% when diagnostic criteria were combined. During the follow-up
period, suspected pancreatitis developed in additional 17–30% cats. Only 1 cat had transient clinical signs compatible with
pancreatitis. Seventeen of the 30 cats (57%) achieved remission. Frequency of abnormal Spec fPL and DGGR-lipase and
abnormal ultrasonographic ﬁndings did not diﬀer in cats achieving remission and those who did not. Cats achieving remis-
sion had signiﬁcantly lower Spec fPL at 2 months (P < .001).
Conclusions and Clinical Importance: Based on laboratory and ultrasonographic measurements, many cats with diabetes
might have pancreatitis, although without clinical signs. Cats with high Spec fPL might have a reduced chance of diabetic
remission; however, this topic needs further studies in large cohorts of diabetic cats.
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Diabetes mellitus (DM) is one of the most commonendocrinopathies in cats. The incidence of DM has
increased in cats because of an increase in predisposing
factors including obesity and physical inactivity.1,2 It has
been suggested that pancreatitis induces DM in cats,3
possibly because of the involvement of the islets of Lan-
gerhans in the inﬂamed exocrine tissue, leading to injury
of the b-cells. However, only a few studies have explored
the association between pancreatitis and DM in cats and
the eﬀect of pancreatitis on glycemic control, and the
results were controversial. One investigation showed his-
tological signs of inﬂammation of the exocrine pancreas
in 19 (51%) of 37 cats with DM examined postmortem;
most cases were chronic but a few were acute to sub-
acute.3 Moreover, achieving good glycemic control
tended to be more diﬃcult in cats in which pancreatic
inﬂammation was documented, suggesting that pancrea-
titis might render insulin treatment less eﬀective.3 In
another study, 24 (83%) of 29 cats with long-standing
DM had increased serum feline pancreatic lipase immu-
noreactivity (fPLI), a marker for pancreatitis, compared
with 15 (66%) of 23 control cats4; diabetic cats also had
signiﬁcantly higher fPLI, suggesting an association
between pancreatitis and the endocrine disease.4 More-
over, there was a positive correlation between increased
fPLI and serum fructosamine concentrations in diabetic
cats, possibly suggesting an adverse eﬀect of pancreatitis
on glycemic control.4 An interesting aspect of both these
studies was that clinical signs were uncommon or not
obvious despite the increased frequency of pancreatitis.
This suggests that exocrine disease is subclinical in the
majority of cats with DM.3,4
The histological prevalence of pancreatitis does not dif-
fer between diabetic cats (21 of 37, 57%) and control cats
(12 of 20, 60%) examined postmortem.a Moreover, cats
with DM and pancreatitis, diagnosed in vivo based on
serum lipase activity measured with the 1,2-o-dilaurylrac-
glycero-3-glutaric acid-(60-methylresoruﬁn) ester (DGGR)
assay, did not show less chances of diabetic remission.5
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These ﬁndings question the association between pancreati-
tis and DM and might suggest that pancreatitis does not
adversely aﬀect metabolic control in diabetic cats.
Diagnosis of pancreatitis is diﬃcult in cats, especially
in subclinical cases.4 At present, the use of serum mark-
ers, such as fPLI or Spec fPL,b combined with abdominal
ultrasonography, are considered the most useful diagnos-
tic parameters to suspect pancreatitis.6 The serum marker
DGGR-lipase activity has recently been shown to corre-
late well with Spec fPL concentration and has therefore
been proposed as an additional diagnostic tool in cats
with suspected pancreatitis.7 Therefore, the aims of this
study were to use the above mentioned serum markers
combined with ultrasonography to prospectively investi-
gate the occurrence of subclinical pancreatitis in cats with
newly diagnosed DM and to monitor the incidence of
subclinical pancreatitis in the follow-up period. In addi-
tion, the rate of diabetic remission was compared in cats
with and without suspected pancreatitis.
Materials and Methods
Animals
Cats with newly diagnosed DM were prospectively enrolled in
the study between July 2008 and January 2011. Cats were excluded
from the study if they had received insulin therapy for longer than
1 week before admission, and if glucocorticoids or progestagens
had been administered during the previous 4 months. On admis-
sion, all cats underwent thorough evaluation including a physical
examination, complete blood cell count, serum biochemistry
including the measurement of fructosamine and total T4 concen-
trations, serum Spec fPL concentration and DGGR-lipase activity,
urinalysis with bacterial culture and urinary protein-to-creatinine
ratio, blood pressure measurement, abdominal and thoracic radi-
ography, and abdominal ultrasonography. Serum Spec fPL con-
centration was measured by IDEXX Laboratories,c,6 and serum
DGGR-lipase activity was measured in the clinical laboratory of
the faculty using a commercial assay.d,7 The study was approved
by the Veterinary Oﬃce of the Canton of Zurich and conducted in
accordance with guidelines established by the Animal Welfare Act
of Switzerland (permission no. 83/2008). The owners provided
informed consent to participate in the study.
Pancreatic Ultrasonography
The pancreas was evaluated during each abdominal ultrasono-
graphic examination by a board-certiﬁed radiologist using a stan-
dardized protocol, which included assessment of pancreatic contour
(regular, irregular) and echogenicity (normal, increased or decreased
compared with liver), thickness of the left and right pancreatic ducts
(normal, increased [>0.25 cm]), and the presence of free ﬂuid or hy-
perechoic mesentery in the vicinity of the pancreas. Ultrasonograph-
ic ﬁndings of the pancreas that were considered abnormal included
irregular contour, increased or decreased echogenicity, increased
duct size, and adjacent free ﬂuid or hyperechoic mesentery.8–10 The
radiologist used the same ultrasonographic protocol in all cats to
reduce bias. The radiologist was informed that the cat was diabetic
but was unaware of the clinical signs and hematology results.
Concurrent Diseases at the Time of Diagnosis
Cats with a concurrent disease (eg, renal failure, gastrointestinal
disorders, heart disease, other endocrinopathies, and neoplasia)
were not included in the study. Diabetic cats with ketoacidosis
were included if acidaemia resolved and the general condition
improved within 48 hours of insulin therapy. Cats suspected of
having clinically relevant pancreatitis were also excluded. Because
results of serum Spec fPL concentration were not available at the
time DM was diagnosed, pancreatitis was suspected and arbitrarily
considered clinically relevant during the initial examination when
at least 1 clinical sign, such as anorexia, vomiting, abdominal pain,
lethargy or hypothermia occurred together with increased DGGR-
lipase activity (>26 U/L)7 or with at least 2 ultrasonographic
abnormalities of the pancreas.
Diabetic Remission and Tests for Pancreatitis During
the Follow-Up Period
During the 6-month follow-up period, the cats were treated
with insulin glarginee and fed a high-protein, low-carbohydrate
diet.f Re-evaluations were scheduled at 1, 2–3, 6–8, 12–16 and
24 weeks. Insulin dosage adjustments were based on clinical signs,
results of physical examination, fructosamine concentration and
blood glucose curves.11 Remission of DM was deﬁned as the
absence of associated clinical signs (eg, polyuria and polydipsia,
polyphagia) accompanied by normal blood glucose (72–162 mg/
dL) and fructosamine concentrations (<340 lmol/L) for at least
4 weeks after discontinuation of insulin treatment.12 The insulin
dosage was gradually decreased in steps of 0.5 UI twice daily, each
week whenever possible. The last dosage before discontinuation of
insulin treatment was 0.5 UI once daily, for at least 1 week. Cats
that required insulin throughout the study were deﬁned as not
being in diabetic remission. During follow-up, diagnostic tests for
the tentative diagnosis of pancreatitis included measurement of
serum Spec fPL concentration and DGGR-lipase activity, as well
as standardized pancreatic ultrasonography. These tests were car-
ried out 2 and 6 months after the time of diagnosis.
Criteria to Suspect Pancreatitis and Statistical
Analysis
Subclinical pancreatitis was suspected at the time of diagnosis
when no clinical signs compatible with pancreatitis were detected
together with 1 or more of the following results: (1) increased Spec
fPL concentration, (2) increased DGGR-lipase activity, (3) at least
2 ultrasonographic abnormalities. A cut-oﬀ value of >5.3 lg/L
was used for Spec fPL concentration.b,g For DGGR-lipase activ-
ity, the cut-oﬀ was set at >26 U/L based on the reference range
previously established in healthy cats (8–26 U/L).7 The same crite-
ria to suspect pancreatitis were also used at the 2- and 6-month
follow-up examinations in cats. The term “suspected” pancreatitis
was used throughout the manuscript because pancreatitis is diﬃ-
cult to diagnose in vivo in cats.
Frequency distributions were constructed for the occurrence of
subclinical pancreatitis on admission and of any form of pancreati-
tis that developed during the follow-up period, based on the afore-
mentioned diagnostic criteria. Fisher’s exact test was used to
examine associations between suspected pancreatitis at the time of
diagnosis or during follow-up and remission of DM. The Mann–
Whitney test followed by Bonferroni correction was used at each
time point for comparison of Spec fPL concentration and DGGR-
lipase activity in cats that achieved diabetic remission and those
that did not. If signiﬁcant diﬀerences were observed, receiver oper-
ating characteristic (ROC) curves were calculated to identify the
cut-oﬀ value with highest sensitivity and speciﬁcity for remission
of DM. Furthermore, the Friedman test followed by Dunn’s mul-
tiple comparison was performed in all cats to verify whether a
decline or increase in Spec fPL concentration and DGGR-lipase
activity occurred during follow-up. A commercial softwareh was
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used for all calculations. Results are presented as median and
ranges, and the level of signiﬁcance was set at P < .05.
Results
Animals
During the study period, 50 cats with newly diagnosed
DM were admitted. Twenty cats were excluded because
of idiopathic hypercalcaemia (3 cats), diabetic ketoacido-
sis with delayed response to treatment (2 cats), suspected
acromegaly (2 cats), pancreatic carcinoma (2 cats), and
one each because of cutaneous mast cell tumor, FIV,
heart failure, hypertension and hepatic cysts, hyperthy-
roidism, ileocolic abscess, injection-site ﬁbrosarcoma,
suspected clinically relevant pancreatitis, plasmacellular
pododermatitis, recent administration of corticosteroids,
and fractious behavior. Thirty cats fulﬁlled the inclusion
criteria and were enrolled in the study. Median age was
11.0 years (range: 7.0–17.0), and median body weight
was 5.0 kg (range: 2.5–9.6). Twenty-ﬁve were domestic
shorthair or longhair cats and 5 were purebred cats,
including one each of Abyssinian, Burmese, Ragdoll,
Siamese and Norwegian forest cat. Seventeen cats were
neutered males and 13 were spayed females. Two of the
enrolled cats had ketoacidosis at presentation with
acidaemia that resolved within 1 day of therapy. None
of the cats had clinical signs compatible with pancreatic
or gastrointestinal disease. The present study is part of a
previously pubished study (Data S1).13
Suspected Pancreatitis at the Time of Diagnosis of
DM
At the time of DM diagnosis, median Spec fPL con-
centration was 3.7 lg/L (range: 0.7–19.7) and median
DGGR-lipase activity was 27 U/L (range: 14–75). Ten
to 15 of the 30 cats (33.3–50.0%) had suspected pancre-
atitis, based on Spec fPL > 5.3 lg/L, DGGR-
lipase > 26 U/L and their combination (Table 1).
Ultrasonography was carried out in 29 of the 30 cats.
Nine of them (31.0%) had ≥2 abnormalities and were
suspected of having pancreatitis (Table 1). Of these 9
cats, 8 had increased or decreased echogenicity of the
pancreas, 4 each had free ﬂuid or hyperechoic mesen-
tery in the vicinity of the pancreas and 3 each had irreg-
ular pancreatic contours or increased size of the left
pancreatic duct. Three of the 9 cats had 4 (1 cat) or 3
(2 cats) concurrent ultrasonographic abnormalities;
none had the same combination of ﬁndings. Of the
remaining 20 cats, all had 1 ultrasonographic abnormal-
ity of the pancreas, including increased or decreased
echogenicity (17 cats), increased size of the right duct (2
cats) and adjacent hyperechoic mesentery (1 cat). Based
on the documentation of ≥2 ultrasonographic abnor-
malities or on the increase of at least one of the serum
markers, pancreatitis was suspected in 9–18 cats (31.0–
60.0%) (Table 1). Three of the 9 cats with suspected
pancreatitis based on ultrasonography had normal Spec
fPL or DGGR-lipase levels.
Suspected Pancreatitis That Developed During the
Follow-Up Period
Two months after diagnosis of DM, median Spec fPL
concentration was 2.6 lg/L (range: 3.2–40.0) and med-
ian DGGR-lipase activity was 24 U/L (range: 12–132);
after 6 months, median Spec fPL concentration was
4.5 lg/L (range: 0.9–>50) and median DGGR-lipase
activity was 29 U/L (range: 10–116). Median Spec fPL
and DGGR-lipase did not diﬀer between time of diag-
nosis and the 2 re-evaluations, nor between the latter 2
time points. The frequency of suspected pancreatitis
was calculated for cats that developed increased serum
markers or abnormal ultrasonographic ﬁndings of the
pancreas during the follow-up period. Pancreatitis at
follow-up was suspected in 5–7 additional cats (16.7–
23.3%) based on Spec fPL concentration, DGGR-lipase
activity and their combinations (Table 1). With regard
to pancreatic ultrasonography, 8 additional cats
(29.6%) had ≥2 abnormal ﬁndings and were thought to
have developed pancreatitis during follow-up (Table 1).
Of these 8 cats, all had increased or decreased echoge-
nicity of the pancreas, 4 each had irregular pancreatic
contours or hyperechoic mesentery in the vicinity of the
pancreas, 2 had increased left pancreatic duct size, and
1 had free ﬂuid adjacent to the pancreas. Based on
Table 1. Diabetic cats with suspected pancreatitis based on increased levels of pancreatic serum markers and ultr-
asonographic abnormalities of the pancreas at the time of diagnosis and during the follow-up period. Cats listed
under follow-up did not have suspected pancreatitis at the time of diagnosis.
Variable
Diagnosis Follow-Up
Cats with Suspected
Pancreatitis (%)
Cats with Suspected
Pancreatitis (%)
Number of Cats at
2 and 6 Months
Spec fPL > 5.3 lg/L 10 of 30 (33) 5 of 30 (17) 2 and 3
DGGR-lipase > 26 U/L 15 of 30 (50) 7 of 30 (23) 2 and 5
Spec fPL > 5.3 lg/L or DGGR-lipase > 26 U/L 15 of 30 (50) 7 of 30 (23) 2 and 5
≥2 ultrasonographic abnormalities 9 of 29 (31) 8 of 27 (30) 4 and 4
≥2 ultrasonographic abnormalities or Spec fPL > 5.3 lg/L 13 of 30 (43) 8 of 29 (28) 3 and 5
≥2 ultrasonographic abnormalities or
DGGR-lipase > 26 U/L
18 of 30 (60) 7 of 30 (23) 2 and 5
≥2 ultrasonographic abnormalities or Spec
fPL > 5.3 lg/L or DGGR-lipase > 26 U/L
18 of 30 (60) 7 of 30 (23) 2 and 5
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documentation of ≥2 ultrasonographic abnormalities or
on increased Spec fPL concentration, DGGR-lipase
activity and their combinations, pancreatitis was sus-
pected in 7–8 additional cats during the follow-up per-
iod (23.3–29.6%) (Table 1).
Signs compatible with clinically relevant pancreatitis
(anorexia and vomiting) occurred in only 1 cat, which
was thought to have developed acute pancreatitis 3 days
after diagnosis of DM. This cat had increased Spec fPL
concentration and DGGR-lipase activity at the time of
diagnosis, but no clinical signs of pancreatitis and only
1 ultrasonographic pancreatic abnormality (hypoechoic
pancreas). Pancreatic ultrasonography during the acute
episode revealed a small amount of abdominal eﬀusion
and hyperechoic mesentery in the vicinity of the pan-
creas in addition to hypoechogenicity of the pancreas.
Although the cat recovered clinically after 8 days, Spec
fPL concentration and DGGR-lipase activity remained
increased and ≥2 ultrasonographic abnormalities were
seen at 2 and 6 months. None of the remaining cats
that were suspected of developing pancreatitis during
follow-up had clinical signs compatible with clinically
relevant pancreatitis.
Follow-Up of Cats with Suspected Pancreatitis at the
Time of Diagnosis
Considering the entire study period, 50.0, 73.3 and
61.8% of cats had suspected pancreatitis based on Spec
fPL, DGGR-lipase and ultrasonography, respectively,
and 86.7% based on any combination of pancreatic
enzymes and ultrasonography (Table 1).
In 8 of 10 (80.0%) cats, in which Spec fPL concentra-
tion was increased, the concentration remained
increased during the follow-up period in 4 and normal-
ized by 2 months but then increased again by 6 months
in the other 4. In the remaining 2 cats with increased
Spec fPL concentration (20.0%) the enzyme levels nor-
malized within 2 months. In 13 of 15 (86.7%) cats, in
which DGGR-lipase was increased, the enzymatic activ-
ity remained elevated during the follow-up period in 11
and normalized by 2 months but then increased again
by 6 months in 2 others. In the remaining 2 cats with
increased DGGR-lipase activity (13.3%) the enzyme
levels normalized within 2 months (Tables 1 and S3).
Four of the 9 cats (44.4%) with ≥2 ultrasonographic
abnormalities of the pancreas continued to have abnor-
mal ﬁndings during the follow-up period. Two had nor-
mal ﬁndings at 6 months and 1 at 2 months, but the
latter had abnormal results at 6 months. The remaining
5 cats (55.6%) with ≥2 pancreatic abnormalities at the
time of diagnosis continued to have a single abnormal
ultrasonographic ﬁnding during the follow-up period
(increased or decreased pancreas echogenicity).
Diabetic Remission and Suspected Pancreatitis
Diabetic remission occurred in 17 of the 30 cats
(56.7%) during the study period. In 8 (47.1%) of these,
remission had occurred by 2 months after the start of
treatment, and in the remaining 9 (52.9%), it occurred
between 2 and 6 months. Two cats in remission
relapsed by 4 and 7 weeks after remission had been
diagnosed, respectively, and the remaining cats
remained in remission until the end of the study. There
were no signiﬁcant associations between diabetic remis-
sion and suspected pancreatitis based on increased
serum markers and ≥2 ultrasonographic abnormalities
at the time of diagnosis or during the follow-up period.
However, based on direct observation of raw data, cats
that did not achieve diabetic remission appeared to
have increased serum markers or ultrasonographic
abnormalities compatible with suspected pancreatitis
more often than cats that had diabetic remission
(Tables 2 and 3).
When absolute levels of Spec fPL and DGGR-lipase
were compared in cats achieving or not diabetic remis-
sion the diﬀerence was only signiﬁcant for Spec fPL at
2 months from admission (Fig 1A,B). Of note, the best
cut-oﬀ value of Spec fPL to identify remission of DM
at 2 months was ≤2.7 lg/L (area under the ROC curve:
0.91; 95% conﬁdence interval: 0.74–0.98); the sensitivity
Table 2. Associations between diabetic remission and pancreatitis based on increased levels of pancreatic serum
markers and ultrasonographic abnormalities of the pancreas at the time of diagnosis. Each parameter is considered
dichotomous (pancreatitis is present or absent). Absolute numbers of cats and percentages are shown.
Variable
Remission (Number of Cats) No Remission (Number of Cats)
Pancreatitis (%) No Pancreatitis (%) Pancreatitis (%) No Pancreatitis (%) P-Value
Spec fPL > 5.3 lg/L 4 (24) 13 (77) 6 (46) 7 (54) .26
DGGR-lipase > 26 U/L 8 (47) 9 (53) 7 (54) 6 (46) 1.00
Spec fPL > 5.3 lg/L or
DGGR-lipase > 26 U/L
8 (47) 9 (53) 7 (54) 6 (46) 1.00
≥2 ultrasonographic abnormalities 3 (18) 14 (82) 6 (46) 7 (54) .12
≥2 ultrasonographic abnormalities or
Spec fPL > 5.3 lg/L
5 (29) 12 (71) 8 (62) 5 (39) .14
≥2 ultrasonographic abnormalities or
DGGR-lipase > 26 U/L
9 (53) 8 (47) 9 (69) 4 (31) .47
≥2 ultrasonographic abnormalities
or Spec fPL > 5.3 lg/L or
DGGR-lipase > 26 U/L
9 (53) 8 (47) 9 (69) 4 (31) .47
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and speciﬁcity of Spec fPL ≤ 2.7 lg/L were 88.2 and
76.9%, respectively.
Increased Spec fPL concentration was accompanied
by increased DGGR-lipase activity in all but 1 of the
29 cats; 1 cat had increased Spec fPL concentration and
normal DGGR-lipase activity (Table S3). Conversely,
17 of the 45 cats with increased DGGR-lipase activity
had normal Spec fPL concentrations. These 17 cats had
median DGGR-lipase of 32 U/L (range 27–67 U/L); 16
of these cats underwent ultrasonographic examination
of the pancreas, which revealed normal ﬁndings in 15
cats and ﬁndings compatible with pancreatitis in 1.
Discussion
This study demonstrated that at the time DM was
diagnosed, up to 60% of cats had suspected subclinical
pancreatitis based on increased serum markers of pan-
creatitis, the occurrence of at least 2 abnormal ultraso-
nographic pancreatic ﬁndings or combinations of these
diagnostic criteria. Furthermore, 17–30% of diabetic
cats were suspected to develop pancreatitis, mostly sub-
clinical, during the 6-month follow-up period. The high
rate of suspected pancreatitis in diabetic cats at the time
of diagnosis and during the follow-up period is in
agreement with the observation that the frequency of
pancreatitis is as high as 83% based on increased fPLI
and 51% based on histological examination.3,4 How-
ever, those retrospective studies included cats with long-
standing disease and did not report the prevalence of
suspected pancreatitis at the time of initial examination.
In this study, the prevalence of suspected pancreatitis at
the time of diagnosis was 50% based on DGGR-lipase
activity, 33% based on Spec fPL concentration and
31% based on ultrasonography of the pancreas. When
ultrasonography was combined with serum markers for
assessment, the prevalence increased to 60%, suggesting
that the former might lead to suspect pancreatitis in
cats with normal serum enzymes. Indeed, 3 of the 9 cats
with suspected pancreatitis based on ultrasonography
did not have increased Spec fPL or DGGR-lipase.
Similar to our ﬁndings, only fair agreement between
ultrasonographic abnormalities and the above serum
markers for the diagnosis of pancreatitis was recently
documented in cats.8 It is also important to note that
the ultrasonographic abnormalities of the pancreas var-
ied among cats with suspected inﬂammation. A variety
of ultrasonographic abnormalities occurred singly or in
combination including changes in echogenicity, the pres-
ence of free ﬂuid or hyperechoic mesentery in the vicin-
ity of the pancreas, and irregular margins. These
features have been variably associated with elevated
fPLI, Spec fPL, or DGGR-lipase in recent studies.8,14,15
During the follow-up period, an additional 17–23%
of cats revealed increased pancreatic enzymes that led
to suspect pancreatitis. On the basis of ultrasonographic
examination, suspected pancreatitis was newly diag-
nosed during follow-up in nearly 30% of cats. This
observation indicates that cats with DM might develop
pancreatitis at some point during the course of the dis-
ease. The relationship between DM and the develop-
ment of pancreatitis is diﬃcult to assess from the
ﬁndings of this study because the number of diabetic
cats was relatively small and there was no control
group. Human beings with type-2 DM had a 3-fold
increase in the risk of pancreatitis, although the cause
has not yet been identiﬁed.16 Healthy cats that under-
went experimental hyperglycemia for 10 days had neutr-
ophilic inﬁltration of the exocrine pancreas, which
suggests a direct eﬀect of excess glucose on the patho-
genesis of pancreatitis.17 However, reports on the risk
of pancreatitis in cats with naturally occurring DM
have been conﬂicting. We observed similar rates of his-
tologically conﬁrmed pancreatitis in diabetic cats and
well matched control catsa while others reported that
diabetic cats had signiﬁcantly higher fPLI than healthy
controls.4
In approximately 80 and 87% of cats that had sus-
pected pancreatitis at the time of diagnosis based on
Spec fPL concentration and DGGR-lipase activity,
respectively, these variables remained increased during
the follow-up period, whereas abnormal pancreatic
Table 3. Associations between diabetic remission and pancreatitis based on increased levels of pancreatic serum
markers and ultrasonographic abnormalities of the pancreas during the follow-up period. Cats with suspected pan-
creatitis at the time of diagnosis are excluded. Results from 2 and 6 months are pooled. Each parameter is consid-
ered dichotomous (pancreatitis is present or absent). Absolute numbers of cats and percentages are shown.
Variable
Remission (Number of Cats) No Remission (Number of Cats)
Pancreatitis (%) No Pancreatitis (%) Pancreatitis (%) No Pancreatitis (%) P-Value
Spec fPL > 5.3 lg/L 3 (23) 10 (77) 2 (29) 5 (71) 1.00
DGGR-lipase > 26 U/L 3 (33) 6 (67) 4 (67) 2 (33) .32
Spec fPL > 5.3 lg/L or
DGGR-lipase > 26 U/L
3 (33) 6 (67) 4 (67) 2 (33) .32
≥2 ultrasonographic abnormalities 5 (42) 7 (58) 3 (50) 3 (50) 1.00
≥2 ultrasonographic abnormalities or
Spec fPL > 5.3 lg/L
5 (46) 6 (55) 3 (60) 2 (40) 1.00
≥2 ultrasonographic abnormalities or
DGGR-lipase > 26 U/L
4 (50) 4 (50) 3 (75) 1 (25) .58
≥2 ultrasonographic abnormalities or Spec
fPL > 5.3 lg/L or DGGR-lipase > 26 U/L
4 (50) 4 (50) 3 (75) 1 (25) .58
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ultrasonographic ﬁndings persisted in only 44% of the
cats. A possible explanation for this diﬀerence is a
lower sensitivity of ultrasonography for diagnosis of
chronic pancreatitis compared with pancreatic enzymes,
but this conﬂicts with a study reporting that ultrasonog-
raphy might be an equally suitable diagnostic method.18
Clinically relevant signs of pancreatitis were not
apparent in any cat with suspected pancreatitis at the
time of diagnosis or during the follow-up period.
Acute pancreatitis was suspected in 1 cat with anorexia
and vomiting a few days after diagnosis of DM. Like-
wise, among the 20 diabetic cats not included in the
study, only 1 had clinical signs suggestive of clinically
relevant pancreatitis. Thus, in agreement with the
results of previous studies,3,4 we found that pancreatitis
is clinically inapparent in the vast majority of diabetic
cats.
It is not clear whether diabetic cats with pancreatitis
have a decreased chance of diabetic remission. Good
glycemic control tended to be more diﬃcult to achieve
in cats with pancreatitis.3 Another study showed a posi-
tive correlation between fPLI and serum fructosamine
concentration,4 suggesting that pancreatitis might
adversely aﬀect b-cells and thus reduces the likelihood
of remission. However, a recent retrospective analysis in
our clinic showed no association between increased
serum DGGR-lipase activity and the rate of diabetic
remission.5
In the present prospective study, increased Spec fPL
concentrations, DGGR-lipase activities and ultrasono-
graphic abnormalities indicative of pancreatitis tended to
be less common in cats that achieved diabetic remission
than in cats that did not, but the diﬀerences were not sig-
niﬁcant. Absolute concentrations of the pancreatic
enzymes were also lower in cats that subsequently
achieved diabetic remission, but the diﬀerence was signif-
icant only for Spec fPL concentration at 2 months from
diagnosis. Spec fPL concentrations ≤2.7 lg/L yielded the
best discriminating power to identify remission of DM if
measured at 2 months. Of note, this value falls within
the normal limits proposed by the laboratory.b,g There-
fore, the clinical relevance of the Spec fPL cut-oﬀ calcu-
lated in this study might be questionable. Whether a
lower Spec fPL cut-oﬀ would be necessary to identify
pancreatitis in diabetic cats deserves further studies.
Taken together, evidence of a detrimental eﬀect of pan-
creatitis on metabolic control in diabetic cats is currently
weak. A recent meta-analysis conducted in people
showed that 15% of patients with acute pancreatitis
developed DM within 12 months of the diagnosis, and
another study revealed that 29% of people with chronic
pancreatitis developed DM over a period of 8 years.19,20
It is possible that a similar relationship exists between
pancreatitis and DM in cats. One proposed cause of DM
in people with pancreatitis is the spread of inﬂammation
from the exocrine pancreas to the islets with subsequent
b-cell damage.19 It is not known whether a similar mech-
anism contributes to DM in cats.
Pancreatitis is diﬃcult to diagnose in cats and ideally
the measurement of pancreatic serum markers and ultr-
asonographic examination should be supplemented by
histological assessment of the pancreas. Unfortunately,
pancreatic biopsy was not feasible in this longitudinal
study of client-owned cats. Diagnostic strategies in the
absence of a gold standard have been reviewed,21,22 but
their use in this study was hampered by the relatively
small number of cases and the fact that Spec fPL and
DGGR-lipase are dependent variables. Indeed, hierar-
chical models require 200–500 cases or more to estimate
test accuracy, and the tests to be compared should be
based on diﬀerent physiological phenomena to avoid
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Fig 1. Scatter plots of Spec fPL serum concentration (A) and
DGGR-lipase activity (B) in diabetic cats with (white dots) and
without remission (black dots) at the time of diagnosis and at 2
and 6 months later. Medians are shown. Dashed lines mark the
upper cut-oﬀ values (5.3 lg/L for Spec fPL, 26 U/L for DGGR-
lipase).
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violation of the conditional independence assump-
tion.21,22
We used 2 serum markers for the tentative diagnosis
of pancreatitis although until recently lipases other than
Spec fPL were considered of limited diagnostic value in
cats. However, it was recently established that the mea-
surements of DGGR-lipase activity and Spec fPL con-
centration essentially agree for cut-oﬀ of the latter set
>5.3 lg/L,g and highly correlate.7 Nonetheless, in this
study, increased DGGR-lipase activity was not accom-
panied by increased Spec fPL concentration in all cats.
A gray zone of measurements that are not very consis-
tent with the occurrence of pancreatitis has been sug-
gested for Spec fPL,b,g and a similar gray zone might
also exist for DGGR-lipase. Indeed, fewer disagree-
ments between the 2 lipases would have occurred if a
higher cut-oﬀ for DGGR-lipase had been used, as dem-
onstrated by the fact that 50% of cases in which
DGGR-lipase activity was increased and Spec fPL con-
centration was normal had DGGR-lipase between 27
and 32 U/L, which was slightly above the reference
range. Finally, because a control group was not
included in this study, it is not known whether sus-
pected pancreatitis was a primary event, or occurred
secondary to DM. We ﬁnd the latter possibility unlikely
considering that histological signs of inﬂammation and
ﬁbrosis of the exocrine pancreas were detected in 45%
of 41 healthy cats, especially older cats.23 It is therefore
possible that DM was responsible for exocrine pancre-
atic disease in only some of the cats.
In summary, this prospective study showed that pan-
creatitis, based on currently used serum markers and
ultrasonographic examination of the pancreas, is com-
mon in cats at the time of diagnosis of DM, and that an
additional portion of the diabetic cats might develop
pancreatitis during the following 6 months. Pancreatitis
was subclinical in almost all cases, and therefore its clini-
cal relevance is questionable. Increased concentrations of
Spec fPL or DGGR-lipase as well as abnormal pancre-
atic ﬁndings on ultrasonography might be associated
with a lower chance of diabetic remission; however, the
study did not reveal a clear statistical evidence.
Footnotes
a Zini E, Lunardi F, Zanetti R, et al. Histological investigation of
endocrine and exocrine pancreas in cats with DM. J Vet Intern
Med 2012;6:1519–1520 (abstract)
b Forman MA, Shiroma J, Armstrong PJ, et al. Evaluation of
feline pancreas-speciﬁc lipase (Spec fPLTM) for the diagnosis of
feline pancreatitis. J Vet Intern Med 2009;23:733–734 (abstract)
c IDEXX GmbH, Ludwigsburg, Germany
d Lipase colorimetric for Roche Cobas Integra 800; Roche Diag-
nostics, Rotkreuz, Switzerland
e Lantus, Sanoﬁ Aventis, Meyrin, Switzerland
f DM Purina Veterinary Diets; Medical solution, Steinhausen,
Switzerland
g http://vetmed.tamu.edu/gilab/service/assays/pli
h GraphPad Prism version 5.0; GraphPad Software, La Jolla, CA
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